Drug Profile


Alternative Names: Gly-Pro-Glu; Glypromate; GPE

Latest Information Update: 12 Apr 2010

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Neuren Pharmaceuticals
  • Class Neuroprotectants; Oligopeptides; Small molecules
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Mild cognitive impairment

Most Recent Events

  • 28 Aug 2006 Clinical data from a media release have been added to the pharmacokinetics section
  • 27 Apr 2006 Neuren Pharmaceuticals has completed a phase II trial in mild cognitive impairment in Australia and New Zealand
  • 06 Jun 2005 Glycine-proline-glutamate has received fast track status for mild cognitive impairment by the US FDA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top